5 Stocks To Watch For December 27, 2021_老虎社区_美港股上老虎

5 Stocks To Watch For December 27, 2021

Benzinga2021-12-27

NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Newbull
·2021-12-27
Generally unheard off coy...can swing either way!
回复
4
举报
收起
- Kazmir:
  yup
  2021-12-27
  回复
  举报
Lenny Sari
·2021-12-27
Like
回复
2
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1164019636?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-27 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164019636","market":"us","top_or_hot":-1,"title":"5 Stocks To Watch For December 27, 2021","media":"Benzinga","content":"<div>\n<p>NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 27, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 27, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021","article_id":"1164019636","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164019636","pubTimestamp":1640598511,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the f","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen","ARES":"Ares Management L.P.","NBSE":"NeuBase Therapeutics Inc.","ESCA":"攀登者"},"translate_title":"2021年12月27日要关注的5只股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEZS":0.9,"ARES":0.9,"ESCA":0.9,"NBSE":0.9,"OCGN":0.9},"content_text":"NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 per share. NeuBase Therapeutics shares gained 0.7% to $3.08 in the after-hours trading session.\nAeterna Zentaris Inc. named Giuliano La Fratta as Chief Financial Officer. Aeterna Zentaris shares fell 0.5% to close at $0.4202 on Thursday.\nAres Management Corporation said its subsidiary, Ares Holdings L.P., agreed to acquire AMP's PrivateMarketsCo Infrastructure Debt platform for $308 million. Ares Management shares gained 3% to settle at $81.36 on Thursday.\nEscalade, Incorporated appointed Walter P. Glazer, Jr. as Chief Executive Officer and President. Escalade shares rose 0.6% to close at $15.69 on Thursday.\nThe Drugs Controller General of India has given Bharat Biotech’s Covaxin Emergency Use approval in the paediatric age group between 12 and 18 years. Ocugen, Inc. has the US rights to the Bharat Biotech’s vaccine candidate. Ocugen shares dropped 1.5% to $5.22 in after-hours trading.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":696963188,"gmtCreate":1640601177046,"gmtModify":1640601177111,"author":{"id":"4101367049328400","authorId":"4101367049328400","name":"Newbull","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4101367049328400","authorIdStr":"4101367049328400"},"htmlText":"Generally unheard off coy...can swing&nbsp;either way!","listText":"Generally unheard off coy...can swing&nbsp;either way!","text":"Generally unheard off coy...can swing either way!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696963188","repostId":1164019636,"repostType":4,"repost":{"id":"1164019636","pubTimestamp":1640598511,"share":"https://www.laohu8.com/m/news/1164019636?lang=&edition=full","pubTime":"2021-12-27 17:48","market":"us","language":"en","title":"5 Stocks To Watch For December 27, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1164019636","media":"Benzinga","summary":"NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the f","content":"<ul>\n <li><b>NeuBase Therapeutics, Inc.</b>&nbsp;reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 per share. NeuBase Therapeutics shares gained 0.7% to $3.08 in the after-hours trading session.</li>\n <li><b>Aeterna Zentaris Inc.</b>&nbsp;named Giuliano La Fratta as Chief Financial Officer. Aeterna Zentaris shares fell 0.5% to close at $0.4202 on Thursday.</li>\n <li><b>Ares Management Corporation</b>&nbsp;said its subsidiary, Ares Holdings L.P., agreed to acquire AMP's PrivateMarketsCo Infrastructure Debt platform for $308 million. Ares Management shares gained 3% to settle at $81.36 on Thursday.</li>\n <li><b>Escalade, Incorporated</b>&nbsp;appointed Walter P. Glazer, Jr. as Chief Executive Officer and President. Escalade shares rose 0.6% to close at $15.69 on Thursday.</li>\n <li>The Drugs Controller General of India has given Bharat Biotech’s Covaxin Emergency Use approval in the paediatric age group between 12 and 18 years.&nbsp;<b>Ocugen, Inc.</b>&nbsp;has the US rights to the Bharat Biotech’s vaccine candidate. Ocugen shares dropped 1.5% to $5.22 in after-hours trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 27, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 27, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NBSE":"NeuBase Therapeutics Inc.","ARES":"Ares Management L.P.","OCGN":"Ocugen","ESCA":"攀登者"},"source_url":"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164019636","content_text":"NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 per share. NeuBase Therapeutics shares gained 0.7% to $3.08 in the after-hours trading session.\nAeterna Zentaris Inc. named Giuliano La Fratta as Chief Financial Officer. Aeterna Zentaris shares fell 0.5% to close at $0.4202 on Thursday.\nAres Management Corporation said its subsidiary, Ares Holdings L.P., agreed to acquire AMP's PrivateMarketsCo Infrastructure Debt platform for $308 million. Ares Management shares gained 3% to settle at $81.36 on Thursday.\nEscalade, Incorporated appointed Walter P. Glazer, Jr. as Chief Executive Officer and President. Escalade shares rose 0.6% to close at $15.69 on Thursday.\nThe Drugs Controller General of India has given Bharat Biotech’s Covaxin Emergency Use approval in the paediatric age group between 12 and 18 years. Ocugen, Inc. has the US rights to the Bharat Biotech’s vaccine candidate. Ocugen shares dropped 1.5% to $5.22 in after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7118844,"gmtCreate":1640602691844,"gmtModify":1640602691953,"authorId":3558609398993628,"author":{"id":3558609398993628,"idStr":"3558609398993628","authorId":3558609398993628,"name":"Kazmir","avatar":"https://static.tigerbbs.com/6fbf34248b52f1c38a9dc30ae20b49d8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696963188,"type":1,"supId":0,"prevId":0,"content":"<u>yup</u>","text":"<u>yup</u>","html":"<u>yup</u>"}],"langContent":"CN"},{"id":696984820,"gmtCreate":1640600175356,"gmtModify":1640600203774,"author":{"id":"4101864922461960","authorId":"4101864922461960","name":"Lenny Sari","avatar":"https://static.tigerbbs.com/24348ddf29c764e6bd01343eba2e92e4","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4101864922461960","authorIdStr":"4101864922461960"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696984820","repostId":1164019636,"repostType":4,"repost":{"id":"1164019636","pubTimestamp":1640598511,"share":"https://www.laohu8.com/m/news/1164019636?lang=&edition=full","pubTime":"2021-12-27 17:48","market":"us","language":"en","title":"5 Stocks To Watch For December 27, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1164019636","media":"Benzinga","summary":"NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the f","content":"<ul>\n <li><b>NeuBase Therapeutics, Inc.</b>&nbsp;reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 per share. NeuBase Therapeutics shares gained 0.7% to $3.08 in the after-hours trading session.</li>\n <li><b>Aeterna Zentaris Inc.</b>&nbsp;named Giuliano La Fratta as Chief Financial Officer. Aeterna Zentaris shares fell 0.5% to close at $0.4202 on Thursday.</li>\n <li><b>Ares Management Corporation</b>&nbsp;said its subsidiary, Ares Holdings L.P., agreed to acquire AMP's PrivateMarketsCo Infrastructure Debt platform for $308 million. Ares Management shares gained 3% to settle at $81.36 on Thursday.</li>\n <li><b>Escalade, Incorporated</b>&nbsp;appointed Walter P. Glazer, Jr. as Chief Executive Officer and President. Escalade shares rose 0.6% to close at $15.69 on Thursday.</li>\n <li>The Drugs Controller General of India has given Bharat Biotech’s Covaxin Emergency Use approval in the paediatric age group between 12 and 18 years.&nbsp;<b>Ocugen, Inc.</b>&nbsp;has the US rights to the Bharat Biotech’s vaccine candidate. Ocugen shares dropped 1.5% to $5.22 in after-hours trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 27, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 27, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NBSE":"NeuBase Therapeutics Inc.","ARES":"Ares Management L.P.","OCGN":"Ocugen","ESCA":"攀登者"},"source_url":"https://www.benzinga.com/news/earnings/21/12/24777190/5-stocks-to-watch-for-december-27-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164019636","content_text":"NeuBase Therapeutics, Inc. reported a net loss of around $25.4 million, or $0.93 per share for the fiscal year ended September 30, 2021, versus a year-ago net loss of around $17.4 million, or $0.89 per share. NeuBase Therapeutics shares gained 0.7% to $3.08 in the after-hours trading session.\nAeterna Zentaris Inc. named Giuliano La Fratta as Chief Financial Officer. Aeterna Zentaris shares fell 0.5% to close at $0.4202 on Thursday.\nAres Management Corporation said its subsidiary, Ares Holdings L.P., agreed to acquire AMP's PrivateMarketsCo Infrastructure Debt platform for $308 million. Ares Management shares gained 3% to settle at $81.36 on Thursday.\nEscalade, Incorporated appointed Walter P. Glazer, Jr. as Chief Executive Officer and President. Escalade shares rose 0.6% to close at $15.69 on Thursday.\nThe Drugs Controller General of India has given Bharat Biotech’s Covaxin Emergency Use approval in the paediatric age group between 12 and 18 years. Ocugen, Inc. has the US rights to the Bharat Biotech’s vaccine candidate. Ocugen shares dropped 1.5% to $5.22 in after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":70,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}